ArticleFrontiers in pharmacology2024

KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis.

Omar S Al-Odat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.